绥美凯治疗期间要注意什么？

It is a targeted drug, but every drug cannot escape one disadvantage, that is, it will produce more or less side effects. The effect is significant, but the side effects are not too great. So what specific issues do you need to pay attention to when taking it?

1. Medication for elderly patients: In patients aged 65 and above, there are limited data on the use of dolutegravir, abacavir and lamivudine. There is no evidence that older patients require different dosages than younger adult patients. Taking into account age-related changes, such as decreased renal function and changes in hematological parameters, special caution is recommended when administering the drug in this age group.

2. It is prohibited to be used in patients with known hypersensitivity to dolutegravir, abacavir, lamivudine or any excipients.

3. It is prohibited to use it in combination with dofetilide and pixicanide.

4. Osteonecrosis

Cases of osteonecrosis have been reported, particularly in patients with recognized risk factors, advanced HIV disease, or long-term exposure to combination antiretroviral therapy (CART). It's unclear how often it occurs.

5. Immune reconstitution inflammatory syndrome

In severely immunocompromised patients infected with HIV, an inflammatory response to asymptomatic or residual opportunistic infections may occur when initiating combination antiretroviral therapy (CART). Autoimmune disorders (e.g., Graves' disease) have also been reported; however, the reported timing of onset is inconsistent and these events may occur many months after initiation of treatment.

6. Chronic hepatitis B or hepatitis C co-infection

In the Phase III study of dolutegravir, patients co-infected with hepatitis B and/or C virus were allowed to be recruited, provided that during the baseline period, liver function test values did not exceed 5 times the upper limit of normal (ULN). Overall, the safety profile in patients with hepatitis B and/or hepatitis C virus infection was similar to that in patients without hepatitis B or C virus infection, but the incidence of AST and ALT abnormalities was higher in the hepatitis B and/or hepatitis C infection subgroup across all treatment groups.

7. Medication for children: The safety and effectiveness of (dolute abalamib tablets) for children under 12 years of age has not yet been determined. No data yet.